Komori
Statutory disclosure document4572Carna Biosciences,Inc.Pharmaceuticals

Report on the Transfer of Shares Allotted Through a Third-Party Allotment

Some of the shares held by the recipient of the third-party allotment were transferred to Macquarie Bank Limited in a bilateral transaction. It explains that the original recipient will continue to bear the economic gains and losses on those shares after the transfer.

Worth reading
53Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
115600
Shares
Wording
Definitive
How definitive the wording is.

Decision and Details

Transfer of shares allotted through a third-party allotment

Implementation13 April 2026 (actual)
AmountTransfer price: ¥412 per share
Quantity / scaleNumber of shares allotted: 1,050,600 shares; number of shares transferred: 115,600 shares
Reason

Because the shares were transferred to a swap position. Athos Asia Event Driven Master Fund continues to enjoy the economic gains and losses from these shares after the transfer.

Decision and Details
ItemDetails
Matter CoveredTransfer of shares allotted through a third-party allotment
Implementation Date13 April 2026 (actual)
AmountTransfer price: ¥412 per share
Quantity / scaleNumber of shares allotted: 1,050,600 shares; number of shares transferred: 115,600 shares
ReasonBecause the shares were transferred to a swap position. Athos Asia Event Driven Master Fund continues to enjoy the economic gains and losses from these shares after the transfer.
Related previous disclosuresDescription dated 11 October 2024 stating that the Company's shares had been allotted through a third-party allotment
Items this document does not state (6)
Decision-Making BodyDecision DatePeriod CoveredImpact on Business PerformanceGoverning RuleFuture plans

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Because the shares were transferred to a swap position. Athos Asia Event Driven Master Fund continues to receive the economic gains and losses on these shares after the transfer.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Report on the Transfer of Shares Allotted Through a Third-Party Allotment | Carna Biosciences,Inc. (4572) timely disclosure | Komori